BiVictriX Therapeutics PLC Pipeline update on BVX002 (1963V)
2023年11月30日 - 4:00PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMBVX
RNS Number : 1963V
BiVictriX Therapeutics PLC
30 November 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")
Pipeline update on lead solid tumour programme, BVX002
-- Emerging data identifies ovarian cancer as one of the lead indications for BVX002, BiVictriX's first-in-class Antibody Drug Conjugate (ADC) targeting solid tumour indications
-- Final antibody sequences selected for BVX002 drug candidate,
Company on track to identify development lead in 2024
-- An updated version of BiVictriX's corporate presentation is
now available on the Company's website
Alderley Park, 30 November 2023 - BiVictriX Therapeutics plc
(AIM: BVX), an emerging biotechnology company applying a
differentiated approach to develop novel, next-generation
anti-cancer precision Antibody Drug Conjugates, offering
substantially improved cancer cell selectivity and therapeutic
activity, announces that the final sequences have been selected for
the Company's second programme, BVX002, targeting solid tumour
indications, with a lead indication in ovarian cancer.
These final antibody sequences, selected from the panel
identified earlier this year, showed strong efficacy and
selectivity towards targeted cancer cells as compared to non-target
cells and passed early assessments of developability.
In addition, emerging data from primary patient samples using a
combination of next generation sequencing techniques and
laboratory-based profiling has generated initial results which
suggest that the antigen fingerprint targeted by BVX002 is present
in multiple solid tumour indications, with especially high
prevalence in high-grade serous ovarian cancer (expressed in
>86% of ovarian cancer patient samples), representing a disease
of significant unmet need and commercial potential for BVX002.
Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics
plc, said: "ADCs have demonstrated incredible promise as an
alternative therapeutic option to current monotherapies and
combination therapies across difficult-to-treat cancers, backed by
high specificity, versatility and selectivity. We have been
encouraged by BiVictriX's progress to date in our lead BVX001
programme for the treatment of Acute Myeloid Leukaemia and are also
pleased by the further development and expansion of our proprietary
ADC pipeline, where BVX002 is showing early promise in targeting
high-grade serous ovarian carcinoma, which accounts for 75% of
epithelial ovarian cancers. We expect to identify a lead
development candidate for BVX002 in 2024 and look forward to
providing our shareholders with further updates as
appropriate."
Corporate Presentation
An updated version of BiVictriX's corporate presentation
reflecting the recent progress made across the BVX001 and BVX002
programmes, as well as the Company's strengthened IP position, is
now available on the Company's website.
ENDS
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non-Executive Email: info@bivictrix.com
Chairman
SP Angel Corporate Finance LLP Tel: +44 (0) 20 3470 0470
(NOMAD and Broker)
David Hignell, Kasia Brzozowska
(Corporate Finance)
Vadim Alexandre, Rob Rees (Sales
and Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886 2500
Broker)
Rupert Dearden/Freddy Crossley/Emma
Earl
ICR Consilium
Mary-Jane Elliott, Namrata Taak, Tel: +44 (0) 20 3709 5700
Max Bennett, Emmalee Hoppe Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a new
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst significantly reducing
treatment-related toxicities.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) Antibody Drug Conjugate
therapeutics which are designed to selectively target
cancer-specific antigen pairs, or "Bi-Cygni(R) fingerprints", on
tumour cells, which are largely absent from healthy cells.
BiVictriX has established a growing proprietary library of
cancer-specific Bi-Cygni(R) fingerprints, which enable the Company
to target a diverse array of different cancer types. The Company
utilises these novel Bi-Cygni(R) fingerprints, together with the
Company's novel Antibody Drug Conjugate therapeutic design, to
develop more effective and safer therapeutics to target cancers
that are expected to constitute orphan indications and areas of
high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDQBLBXXFLFFBB
(END) Dow Jones Newswires
November 30, 2023 02:00 ET (07:00 GMT)
Bivictrix Therapeutics (LSE:BVX)
過去 株価チャート
から 3 2024 まで 4 2024
Bivictrix Therapeutics (LSE:BVX)
過去 株価チャート
から 4 2023 まで 4 2024
